Pfizer

FDA Approves Supplemental Applications for ZYVOX by Pfizer

The FDA has approved supplemental applications for ZYVOX (linezolid), indicating ongoing support for this antibiotic.

FDA Grants Priority Review for Pfizer's Marstacimab (HYMPAVZI) Supplement

The FDA has granted priority review status for the supplemental application of Marstacimab (HYMPAVZI) by Pfizer.

Pilot Study on Text-Based Contingency Management for Smoking Cessation Engagement

A pilot study is assessing the feasibility of a text-based contingency management intervention to enhance engagement in smoking cessation treatment.

Study on Host-Pathogen Interaction with Staphylococcus aureus Using Lymphoid Organoids

A study is being conducted to understand the interaction between Staphylococcus aureus and human cells using tonsil tissues.

Study Reveals Mucus-Plug Dynamics in COPD Patients and Ex-Smokers

In a study of ex-smokers, mucus-plugs persisted in one-third of patients with COPD, while new plugs developed in others, indicating complex dynamics.

Study Evaluates ePRO Follow-Up for Oncology Patients Post-Hospitalization

The study assesses the feasibility of using electronic patient-reported outcomes (ePRO) and transitional nurse consultations for oncology patients post-discharge.

ACT vs CBT Trial for Psychological Distress in HIV/AIDS Patients

A randomized controlled trial is underway comparing Acceptance and Commitment Therapy and Cognitive Behavioral Therapy in HIV/AIDS patients.

ComboMATCH Trial Targets Genetic Mutations in Advanced Solid Tumors

The ComboMATCH trial aims to match patients with advanced solid tumors to targeted therapies based on genetic testing.

Cardiff Oncology and Pfizer assess onvansertib in metastatic colorectal cancer trial

A clinical trial is underway to evaluate onvansertib combined with standard therapies for first-line treatment of KRAS/NRAS-mutated metastatic colorectal cancer.

FDA Draft Guidance Aims to Reduce Animal Testing for Cancer Drugs

The FDA has issued draft guidance to minimize unnecessary animal testing in the development of cancer drugs.

Study on Exercise Program's Impact on Quality of Life in Prostate Cancer Patients

A clinical trial is assessing the effects of a structured exercise program on quality of life and health outcomes in prostate cancer patients.

Study Reveals Risk Factors for Second Primary Cancer in Colorectal Cancer Survivors

The study identifies age, neoadjuvant therapy, and tumor characteristics as risk factors for second primary cancer in colorectal cancer survivors.

Study on Socio-aesthetics Care Impact on Cancer Patients' Quality of Life

A randomized controlled trial is evaluating the impact of socio-aesthetics well-being care on quality of life, pain, and anxiety in cancer patients.

Pfizer's Phase 3 Study of Tofacitinib in Pediatric Ulcerative Colitis Underway

Pfizer's ELREXFIO Shows Significant PFS Improvement in RRMM Patients

The Phase 3 MagnetisMM-5 trial demonstrated a statistically significant improvement in progression-free survival for ELREXFIO in patients with relapsed or refractory multiple myeloma compared to standard-of-care.

European Commission Approves Pfizer’s HYMPAVZI for Hemophilia A and B Treatment

The European Commission has approved HYMPAVZI for treating hemophilia A or B in patients 12 years and older with inhibitors, based on Phase 3 data showing significant bleed reduction.

Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3

Pfizer and Innovent Collaborate on 12 Early-Stage Oncology Programs

Pfizer and Innovent Biologics have entered a strategic collaboration to co-develop 12 early-stage cancer medicines, including antibody-drug conjugates.

Pfizer's Berobenatide Shows Promising Phase 2b Results for Monthly Dosing in Obesity Management

Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC

The seven-year analysis of the CROWN trial shows a 55% likelihood of remaining alive without disease progression for patients treated with LORBRENA, with median progression-free survival not reached.

TALZENNA Plus XTANDI Shows 52% rPFS Improvement in Metastatic Prostate Cancer

The Phase 3 TALAPRO-3 study demonstrated that TALZENNA plus XTANDI significantly improved radiographic progression-free survival (rPFS) by 52% in patients with HRR gene-altered metastatic prostate cancer.

Pfizer’s BRAFTOVI Regimen Nearly Doubles Progression-Free Survival in mCRC

The Phase 3 BREAKWATER study showed BRAFTOVI combined with cetuximab and FOLFIRI nearly doubled median progression-free survival to 15.2 months compared to 8.3 months with the comparator.

FDA Approves Pfizer’s HYMPAVZI for Expanded Hemophilia A and B Indications

The FDA has approved an expanded indication for Pfizer’s HYMPAVZI to treat hemophilia A or B in patients aged 6 and older, including those with inhibitors.

FDA Approves Supplemental Applications for ZYVOX by Pfizer

The FDA has approved supplemental applications for ZYVOX (linezolid), indicating ongoing support for this antibiotic.

FDA Grants Priority Review for Pfizer's Marstacimab (HYMPAVZI) Supplement

The FDA has granted priority review status for the supplemental application of Marstacimab (HYMPAVZI) by Pfizer.

FDA Draft Guidance Aims to Reduce Animal Testing for Cancer Drugs

The FDA has issued draft guidance to minimize unnecessary animal testing in the development of cancer drugs.

European Commission Approves Pfizer’s HYMPAVZI for Hemophilia A and B Treatment

The European Commission has approved HYMPAVZI for treating hemophilia A or B in patients 12 years and older with inhibitors, based on Phase 3 data showing significant bleed reduction.

FDA Approves Pfizer’s HYMPAVZI for Expanded Hemophilia A and B Indications

The FDA has approved an expanded indication for Pfizer’s HYMPAVZI to treat hemophilia A or B in patients aged 6 and older, including those with inhibitors.

Pilot Study on Text-Based Contingency Management for Smoking Cessation Engagement

A pilot study is assessing the feasibility of a text-based contingency management intervention to enhance engagement in smoking cessation treatment.

Study on Host-Pathogen Interaction with Staphylococcus aureus Using Lymphoid Organoids

A study is being conducted to understand the interaction between Staphylococcus aureus and human cells using tonsil tissues.

Study Reveals Mucus-Plug Dynamics in COPD Patients and Ex-Smokers

In a study of ex-smokers, mucus-plugs persisted in one-third of patients with COPD, while new plugs developed in others, indicating complex dynamics.

Study Evaluates ePRO Follow-Up for Oncology Patients Post-Hospitalization

The study assesses the feasibility of using electronic patient-reported outcomes (ePRO) and transitional nurse consultations for oncology patients post-discharge.

ACT vs CBT Trial for Psychological Distress in HIV/AIDS Patients

A randomized controlled trial is underway comparing Acceptance and Commitment Therapy and Cognitive Behavioral Therapy in HIV/AIDS patients.

ComboMATCH Trial Targets Genetic Mutations in Advanced Solid Tumors

The ComboMATCH trial aims to match patients with advanced solid tumors to targeted therapies based on genetic testing.

Cardiff Oncology and Pfizer assess onvansertib in metastatic colorectal cancer trial

A clinical trial is underway to evaluate onvansertib combined with standard therapies for first-line treatment of KRAS/NRAS-mutated metastatic colorectal cancer.

Study on Exercise Program's Impact on Quality of Life in Prostate Cancer Patients

A clinical trial is assessing the effects of a structured exercise program on quality of life and health outcomes in prostate cancer patients.

Study Reveals Risk Factors for Second Primary Cancer in Colorectal Cancer Survivors

The study identifies age, neoadjuvant therapy, and tumor characteristics as risk factors for second primary cancer in colorectal cancer survivors.

Study on Socio-aesthetics Care Impact on Cancer Patients' Quality of Life

A randomized controlled trial is evaluating the impact of socio-aesthetics well-being care on quality of life, pain, and anxiety in cancer patients.

Pfizer's Phase 3 Study of Tofacitinib in Pediatric Ulcerative Colitis Underway

Pfizer's ELREXFIO Shows Significant PFS Improvement in RRMM Patients

The Phase 3 MagnetisMM-5 trial demonstrated a statistically significant improvement in progression-free survival for ELREXFIO in patients with relapsed or refractory multiple myeloma compared to standard-of-care.

Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3

Pfizer's Berobenatide Shows Promising Phase 2b Results for Monthly Dosing in Obesity Management

Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC

The seven-year analysis of the CROWN trial shows a 55% likelihood of remaining alive without disease progression for patients treated with LORBRENA, with median progression-free survival not reached.

TALZENNA Plus XTANDI Shows 52% rPFS Improvement in Metastatic Prostate Cancer

The Phase 3 TALAPRO-3 study demonstrated that TALZENNA plus XTANDI significantly improved radiographic progression-free survival (rPFS) by 52% in patients with HRR gene-altered metastatic prostate cancer.

Pfizer’s BRAFTOVI Regimen Nearly Doubles Progression-Free Survival in mCRC

The Phase 3 BREAKWATER study showed BRAFTOVI combined with cetuximab and FOLFIRI nearly doubled median progression-free survival to 15.2 months compared to 8.3 months with the comparator.

Pfizer and Innovent Collaborate on 12 Early-Stage Oncology Programs

Pfizer and Innovent Biologics have entered a strategic collaboration to co-develop 12 early-stage cancer medicines, including antibody-drug conjugates.